During a medication review for an 80-year-old man with heart failure, atrial fibrillation, type 2 diabetes, and benign prostatic hyperplasia, you note he is taking warfarin (INR target 2-3), furosemide, bisoprolol, ramipril, metformin, tamsulosin, and has recently been prescribed trimethoprim by an out-of-hours service for a urinary tract infection. He is due to collect his prescription today. What is the MOST important immediate action?
Q152
A 73-year-old woman with type 2 diabetes, ischaemic heart disease, and chronic kidney disease stage 3a attends for review. She takes aspirin, clopidogrel, atorvastatin, bisoprolol, ramipril, metformin, and omeprazole. Recent blood tests show: eGFR 52 ml/min/1.73m², HbA1c 51 mmol/mol, potassium 5.2 mmol/L. She reports no symptoms of angina or heart failure. According to current evidence-based guidelines, what is the primary rationale for her dual antiplatelet therapy?
Q153
A 76-year-old man presents for his annual chronic disease review. He has type 2 diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and osteoarthritis. His current medications include metformin, gliclazide, ramipril, amlodipine, salbutamol inhaler, tiotropium inhaler, and regular co-codamol. His HbA1c is 48 mmol/mol, blood pressure 138/82 mmHg, and eGFR 58 ml/min/1.73m². What is the MOST appropriate definition of his condition according to current UK guidance?
Q154
You are reviewing prescribing data for your practice and note that 15% of patients over 75 are taking 10 or more regular medications. According to current evidence and UK guidance on managing polypharmacy in primary care, which statement best describes the relationship between the number of medications and clinical outcomes in older adults?
Q155
A 77-year-old man attends for a comprehensive medication review. He has heart failure (NYHA II), atrial fibrillation, COPD (GOLD stage 2), osteoarthritis, and benign prostatic hyperplasia. His medication list includes: bisoprolol 5mg OD, ramipril 10mg OD, furosemide 40mg OD, apixaban 5mg BD, tiotropium 18mcg OD, salbutamol PRN, paracetamol 1g QDS, codeine 30mg QDS, tamsulosin 400mcg OD, finasteride 5mg OD, and omeprazole 20mg OD. He reports chronic constipation and poor mobility. Applying prescribing principles for multimorbidity, which represents the most appropriate deprescribing priority?
Q156
A 71-year-old woman with Parkinson's disease, osteoporosis, hypertension, and recurrent UTIs is brought by her family due to acute confusion and visual hallucinations over the past 48 hours. Her medications include co-careldopa 25/100mg QDS, pramipexole 1.05mg TDS, bisoprolol 2.5mg OD, amlodipine 5mg OD, alendronic acid 70mg weekly, calcium/vitamin D supplementation, and oxybutynin 5mg TDS (started 1 week ago for urinary frequency). Temperature is 37.2°C, BP 135/78 mmHg, and urinalysis shows 2+ leucocytes, 1+ protein, no nitrites. What is the most likely cause of her acute deterioration requiring immediate medication adjustment?
Q157
During a structured medication review using the STOPP/START criteria, you identify that an 80-year-old man with heart failure (LVEF 35%), atrial fibrillation, hypertension, and type 2 diabetes is not taking a beta-blocker. His current medications include digoxin 125mcg OD, furosemide 40mg BD, ramipril 5mg OD, apixaban 5mg BD, metformin 500mg BD, and simvastatin 40mg nocte. His heart rate is 76 bpm and blood pressure is 142/86 mmHg. Which principle of the START criteria is most relevant to this clinical scenario?
Q158
A 69-year-old man with COPD, ischaemic heart disease, type 2 diabetes, and depression presents with recurrent falls. He is taking tiotropium 18mcg OD, salmeterol/fluticasone 25/250mcg BD, bisoprolol 5mg OD, aspirin 75mg OD, atorvastatin 40mg OD, metformin 1g BD, lisinopril 10mg OD, mirtazapine 30mg nocte, and diazepam 5mg BD for anxiety. Examination shows postural hypotension (lying BP 138/82 mmHg, standing BP 110/68 mmHg). Which medication change would most effectively reduce his fall risk while maintaining optimal chronic disease management?
Q159
You are conducting a medication review for a 75-year-old woman with type 2 diabetes, ischaemic heart disease, heart failure (NYHA class II), and chronic kidney disease stage 3a. Her medications include metformin 1g BD, gliclazide 160mg BD, ramipril 10mg OD, bisoprolol 10mg OD, furosemide 40mg OD, spironolactone 25mg OD, aspirin 75mg OD, and atorvastatin 80mg OD. Her HbA1c is 52 mmol/mol, eGFR is 48 mL/min/1.73m², and potassium is 5.2 mmol/L. Which medication requires the most urgent review?
Q160
An 82-year-old man with heart failure, chronic kidney disease stage 3b, benign prostatic hyperplasia, and insomnia has been taking temazepam 10mg nocte for the past 8 years. He attends asking for a repeat prescription. His other medications include furosemide 40mg OD, ramipril 5mg OD, bisoprolol 2.5mg OD, and tamsulosin 400mcg OD. He reports that the temazepam 'works well' and he is reluctant to stop it. What is the most appropriate management approach regarding his benzodiazepine use?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 151: During a medication review for an 80-year-old man with heart failure, atrial fibrillation, type 2 diabetes, and benign prostatic hyperplasia, you note he is taking warfarin (INR target 2-3), furosemide, bisoprolol, ramipril, metformin, tamsulosin, and has recently been prescribed trimethoprim by an out-of-hours service for a urinary tract infection. He is due to collect his prescription today. What is the MOST important immediate action?
A. Contact the patient urgently to advise INR monitoring within 3-5 days due to warfarin interaction (Correct Answer)
B. Switch trimethoprim to nitrofurantoin to avoid warfarin interaction
C. Reduce warfarin dose prophylactically while on trimethoprim
D. Advise the patient to stop warfarin temporarily during antibiotic course
E. Arrange hospital admission for IV antibiotics to avoid oral drug interactions
Explanation: ***Contact the patient urgently to advise INR monitoring within 3-5 days due to warfarin interaction*** - **Trimethoprim** inhibits the metabolism of **warfarin**, significantly increasing the **INR** and elevating the risk of life-threatening bleeding. - The current gold standard for managing this interaction is close **biochemical monitoring** (typically within 3-5 days) rather than preemptive dose adjustment. *Switch trimethoprim to nitrofurantoin to avoid warfarin interaction* - While **nitrofurantoin** has a lower interaction profile with warfarin, it is often contraindicated in elderly patients with **heart failure** and potential renal impairment (eGFR <45). - Clinical guidelines prioritize managing the existing prescription through monitoring unless the patient is already at a high baseline bleeding risk. *Reduce warfarin dose prophylactically while on trimethoprim* - Prophylactic dose reduction is risky because the **magnitude of interaction** varies significantly between individuals, potentially leading to sub-therapeutic levels. - **Under-anticoagulation** in a patient with **atrial fibrillation** creates an unnecessary risk of thromboembolic events like stroke. *Advise the patient to stop warfarin temporarily during antibiotic course* - Temporarily stopping warfarin for a simple UTI is inappropriate and dangerously increases the risk of **ischaemic stroke**. - Managing the interaction through **INR monitoring** ensures the patient remains within the therapeutic window safely. *Arrange hospital admission for IV antibiotics to avoid oral drug interactions* - Hospital admission for an **uncomplicated UTI** is unnecessary and increases the risk of hospital-acquired infections and delirium in an 80-year-old. - **Drug interactions** should be managed in the primary care setting through appropriate monitoring and patient education.
Question 152: A 73-year-old woman with type 2 diabetes, ischaemic heart disease, and chronic kidney disease stage 3a attends for review. She takes aspirin, clopidogrel, atorvastatin, bisoprolol, ramipril, metformin, and omeprazole. Recent blood tests show: eGFR 52 ml/min/1.73m², HbA1c 51 mmol/mol, potassium 5.2 mmol/L. She reports no symptoms of angina or heart failure. According to current evidence-based guidelines, what is the primary rationale for her dual antiplatelet therapy?
A. Standard long-term treatment for all patients with ischaemic heart disease
B. Time-limited therapy following acute coronary syndrome or coronary intervention (Correct Answer)
C. Prevention of stroke in patients with chronic kidney disease
D. Enhanced cardiovascular protection when combined with ACE inhibitors
E. Mandatory therapy for diabetic patients with cardiovascular disease
Explanation: ***Time-limited therapy following acute coronary syndrome or coronary intervention*** - **Dual antiplatelet therapy (DAPT)**, such as aspirin and clopidogrel, is specifically indicated for a **limited duration** (usually 6-12 months) after an **ACS** or **stent insertion** to prevent thrombosis. - In stable **ischaemic heart disease**, continuing DAPT long-term is generally avoided because the **bleeding risk** eventually outweighs the cardiovascular benefits. *Standard long-term treatment for all patients with ischaemic heart disease* - Long-term management of stable IHD typically involves **mono-antiplatelet therapy** (usually aspirin or clopidogrel alone), not both. - Chronic use of DAPT without a specific recent vascular event significantly increases the risk of **gastrointestinal haemorrhage**. *Prevention of stroke in patients with chronic kidney disease* - While CKD increases cardiovascular risk, **DAPT** is not the standard regimen for stroke prevention in these patients unless they have specific cardiovascular indications. - Anticoagulants, rather than DAPT, are the primary choice for **ischaemic stroke prevention** in specific conditions like **atrial fibrillation**. *Enhanced cardiovascular protection when combined with ACE inhibitors* - There is no evidence that DAPT provides a synergistic effect specifically when used with **ACE inhibitors** like ramipril. - ACE inhibitors are used for **blood pressure control** and **renal protection**, while DAPT is used specifically for its **anti-thrombotic properties** in the arterial system. *Mandatory therapy for diabetic patients with cardiovascular disease* - Diabetes is a high-risk factor, but it does not make **long-term DAPT** mandatory; management focuses on tight **HbA1c control** and **statin therapy**. - Evidence-based guidelines emphasize **mono-antiplatelet therapy** for diabetic patients with stable macrovascular disease to balance efficacy and safety.
Question 153: A 76-year-old man presents for his annual chronic disease review. He has type 2 diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and osteoarthritis. His current medications include metformin, gliclazide, ramipril, amlodipine, salbutamol inhaler, tiotropium inhaler, and regular co-codamol. His HbA1c is 48 mmol/mol, blood pressure 138/82 mmHg, and eGFR 58 ml/min/1.73m². What is the MOST appropriate definition of his condition according to current UK guidance?
A. Multimorbidity defined as having two or more long-term health conditions (Correct Answer)
B. Polypharmacy defined as taking five or more regular medications
C. Complex multimorbidity due to involvement of three or more body systems
D. Medication overload requiring immediate deprescribing
E. Multiple pathology requiring specialist referral
Explanation: ***Multimorbidity defined as having two or more long-term health conditions***
- This is the standard definition used by **NICE (NG56)**, referring to the presence of two or more long-term health conditions in a single individual.
- The patient meets this criteria as he has four distinct long-term conditions: **type 2 diabetes**, **hypertension**, **COPD**, and **osteoarthritis**.
*Polypharmacy defined as taking five or more regular medications*
- While this patient is experiencing **polypharmacy** (taking 7 unique medications), this describes his treatment regimen rather than his overall clinical condition.
- Polypharmacy is often a consequence of **multimorbidity**, but it is not the primary definition for the coexistence of multiple chronic diseases.
*Complex multimorbidity due to involvement of three or more body systems*
- **Complex multimorbidity** is sometimes used to describe the involvement of multiple systems, but it is not the standard term used in overarching **UK guidance** for general diagnosis.
- The baseline definition for identifying these patients for review remains the presence of **two or more** conditions.
*Medication overload requiring immediate deprescribing*
- **Medication overload** is a clinical judgment, and in this case, his markers (HbA1c 48, BP 138/82) suggest his conditions are **well-controlled** on his current regimen.
- There is no clinical evidence of toxicity or adverse interactions presented that would necessitate **immediate deprescribing** at this review.
*Multiple pathology requiring specialist referral*
- **Multiple pathology** is an older term and does not denote an automatic need for **specialist referral**.
- These conditions are characteristically managed within **primary care** using a holistic, patient-centered approach rather than fragmented specialist care.
Question 154: You are reviewing prescribing data for your practice and note that 15% of patients over 75 are taking 10 or more regular medications. According to current evidence and UK guidance on managing polypharmacy in primary care, which statement best describes the relationship between the number of medications and clinical outcomes in older adults?
A. Medication reviews should only be conducted annually for patients on multiple medications
B. Polypharmacy (≥5 medications) is always inappropriate and should be actively reduced
C. The number of medications is less important than the appropriateness of each individual medication (Correct Answer)
D. Patients taking ≥10 medications should be referred to clinical pharmacy for specialist review
E. Polypharmacy increases mortality regardless of the appropriateness of prescribing
Explanation: ***The number of medications is less important than the appropriateness of each individual medication***
- Current UK guidance emphasizes **appropriate polypharmacy**, where multiple medications are correctly prescribed to manage complex **multimorbidity** according to evidence-based guidelines.
- Clinical focus should shift from the raw number of drugs to identifying **problematic polypharmacy**, where risks like **adverse drug reactions** outweigh the therapeutic benefits.
*Medication reviews should only be conducted annually for patients on multiple medications*
- Patients with complex needs or **high-risk medications** often require more frequent monitoring than a standard **annual review** to ensure safety.
- NICE guidelines advocate for **individualised intervals** based on clinical stability and the risk of drug-drug interactions.
*Polypharmacy (≥5 medications) is always inappropriate and should be actively reduced*
- Polypharmacy is defined as taking 5 or more drugs, but it can be **appropriate** if each drug is clinically indicated and preferred by the patient.
- **Deprescribing** should be based on clinical need and **shared decision-making** rather than arbitrary thresholds for the number of tablets.
*Patients taking ≥10 medications should be referred to clinical pharmacy for specialist review*
- While clinical pharmacists are vital in **medicines optimisation**, primary care physicians are also responsible for conducting regular **structured medication reviews**.
- Referral is based on **complexity** and the risk of harm rather than a mandatory numerical trigger of ten medications.
*Polypharmacy increases mortality regardless of the appropriateness of prescribing*
- The association between polypharmacy and mortality is often **confounded by indication**, as patients with more severe underlying illnesses naturally require more medication.
- **Appropriate polypharmacy** is intended to improve quality of life and outcomes, whereas only **inappropriate prescribing** is consistently linked to increased preventable mortality.
Question 155: A 77-year-old man attends for a comprehensive medication review. He has heart failure (NYHA II), atrial fibrillation, COPD (GOLD stage 2), osteoarthritis, and benign prostatic hyperplasia. His medication list includes: bisoprolol 5mg OD, ramipril 10mg OD, furosemide 40mg OD, apixaban 5mg BD, tiotropium 18mcg OD, salbutamol PRN, paracetamol 1g QDS, codeine 30mg QDS, tamsulosin 400mcg OD, finasteride 5mg OD, and omeprazole 20mg OD. He reports chronic constipation and poor mobility. Applying prescribing principles for multimorbidity, which represents the most appropriate deprescribing priority?
A. Codeine due to contributing to constipation and fall risk with limited benefit (Correct Answer)
B. Tamsulosin as it may worsen postural hypotension when combined with other antihypertensives
C. Finasteride as it takes months to work and may cause sexual dysfunction
D. Paracetamol as regular use increases cardiovascular risk in heart failure
E. Omeprazole as there is no documented indication for gastroprotection
Explanation: ***Codeine due to contributing to constipation and fall risk with limited benefit***
- **Codeine** is an opioid that significantly exacerbates **chronic constipation** through its action on mu-receptors in the GI tract, and its sedative properties increase **fall risk** in older adults with poor mobility.
- In elderly patients with **osteoarthritis**, the long-term benefit of weak opioids like codeine is often minimal compared to the substantial risks of **cognitive impairment**, **respiratory depression** (especially with **COPD**), and **dependency**.
*Tamsulosin as it may worsen postural hypotension when combined with other antihypertensives*
- While **tamsulosin** can cause **postural hypotension**, it provides crucial symptomatic relief for **benign prostatic hyperplasia (BPH)** and significantly improves the patient's quality of life by reducing urinary symptoms.
- Abrupt cessation could lead to **acute urinary retention** or worsening of lower urinary tract symptoms, making it a lower priority for deprescribing compared to a medication with direct, ongoing harm like codeine.
*Finasteride as it takes months to work and may cause sexual dysfunction*
- **Finasteride** is prescribed to reduce prostate size, prevent BPH progression, and reduce the risk of acute urinary retention; its benefits are long-term and may take months to become evident.
- Although **sexual dysfunction** is a known side effect, it is often present in this demographic, and the drug's role in preventing long-term BPH complications is valuable, outweighing the immediate need for deprescribing.
*Paracetamol as regular use increases cardiovascular risk in heart failure*
- There is no strong clinical evidence to support a direct increase in **cardiovascular risk** in **heart failure** patients with regular use of **paracetamol** at recommended doses.
- **Paracetamol** remains the preferred first-line analgesic for **osteoarthritis** as it lacks the significant gastrointestinal and renal toxicities associated with NSAIDs, making it safer for this multimorbid patient.
*Omeprazole as there is no documented indication for gastroprotection*
- While the specific indication for **omeprazole** is not documented, in a multimorbid elderly patient, it often serves as gastroprotection, especially considering the potential for **NSAID use** (even over-the-counter) or other risk factors for **peptic ulcer disease**.
- Deprescribing a **proton pump inhibitor (PPI)** can lead to **rebound acid hypersecretion** and worsening reflux symptoms, making it a secondary priority compared to addressing the immediate harms caused by codeine.
Question 156: A 71-year-old woman with Parkinson's disease, osteoporosis, hypertension, and recurrent UTIs is brought by her family due to acute confusion and visual hallucinations over the past 48 hours. Her medications include co-careldopa 25/100mg QDS, pramipexole 1.05mg TDS, bisoprolol 2.5mg OD, amlodipine 5mg OD, alendronic acid 70mg weekly, calcium/vitamin D supplementation, and oxybutynin 5mg TDS (started 1 week ago for urinary frequency). Temperature is 37.2°C, BP 135/78 mmHg, and urinalysis shows 2+ leucocytes, 1+ protein, no nitrites. What is the most likely cause of her acute deterioration requiring immediate medication adjustment?
A. Urinary tract infection requiring antibiotic treatment
B. Dopamine agonist psychosis from pramipexole
C. Acute worsening of Parkinson's disease requiring dose increase
D. Anticholinergic effects from oxybutynin causing delirium (Correct Answer)
E. Hypercalcaemia from calcium supplementation
Explanation: ***Anticholinergic effects from oxybutynin causing delirium***
- The temporal link between starting **oxybutynin** one week ago and the onset of **acute confusion** and hallucinations strongly indicates drug-induced **delirium**.
- Patients with **Parkinson’s disease** are highly susceptible to central **anticholinergic side effects** because they have an underlying cholinergic deficit in the brain.
*Urinary tract infection requiring antibiotic treatment*
- While the urinalysis shows **leucocytes**, the absence of **nitrites** and lack of high fever makes a UTI a less likely primary trigger for acute delirium compared to the new medication.
- Recurrent UTIs are common, but the introduction of a high-risk medication like **oxybutynin** is a more immediate pharmacological concern for acute mental status changes.
*Dopamine agonist psychosis from pramipexole*
- **Pramipexole** can cause visual hallucinations, but the patient has likely been stable on this dose, making it less likely than the recently introduced **anticholinergic** agent.
- Psychosis from stable Parkinson's medications typically develops gradually or with dose increases, not as an acute 48-hour deterioration in a stable regimen.
*Acute worsening of Parkinson's disease requiring dose increase*
- Parkinson's disease progression typically involves a **gradual worsening** of motor and non-motor symptoms; an acute onset of severe confusion and hallucinations points to an acute precipitant like **delirium**, not typical disease progression.
- Increasing the **dopaminergic dose** in a patient experiencing acute psychosis would likely worsen the hallucinations and confusion rather than improve them.
*Hypercalcaemia from calcium supplementation*
- Standard **calcium and vitamin D** supplementation for osteoporosis is unlikely to cause hypercalcaemia severe enough to induce acute delirium.
- Hypercalcaemia typically presents with symptoms like **polyuria**, **polydipsia**, **constipation**, and muscle weakness, and is usually associated with underlying conditions such as malignancy or hyperparathyroidism.
Question 157: During a structured medication review using the STOPP/START criteria, you identify that an 80-year-old man with heart failure (LVEF 35%), atrial fibrillation, hypertension, and type 2 diabetes is not taking a beta-blocker. His current medications include digoxin 125mcg OD, furosemide 40mg BD, ramipril 5mg OD, apixaban 5mg BD, metformin 500mg BD, and simvastatin 40mg nocte. His heart rate is 76 bpm and blood pressure is 142/86 mmHg. Which principle of the START criteria is most relevant to this clinical scenario?
A. Beta-blockers should be prescribed for all patients with atrial fibrillation for rate control
B. Beta-blockers are indicated in systolic heart failure unless contraindicated (Correct Answer)
C. Beta-blockers should be added when ACE inhibitors alone fail to control blood pressure
D. Beta-blockers are recommended in diabetes to reduce cardiovascular risk
E. Beta-blockers should replace digoxin in elderly patients with heart failure
Explanation: ***Beta-blockers are indicated in systolic heart failure unless contraindicated***
- The patient has **heart failure with reduced ejection fraction (LVEF 35%)**, for which beta-blockers are a cornerstone therapy recommended by **START criteria** to reduce mortality and morbidity.
- Despite current medications, the absence of a beta-blocker represents a significant omission in managing his **systolic heart failure**.
*Beta-blockers should be prescribed for all patients with atrial fibrillation for rate control*
- While beta-blockers are important for **atrial fibrillation rate control**, the patient's heart rate is already 76 bpm on **digoxin**, suggesting his rate is adequately controlled.
- The **START criteria**'s priority in this scenario is the **prognostic benefit** of beta-blockers in **systolic heart failure**, rather than solely for rate control.
*Beta-blockers should be added when ACE inhibitors alone fail to control blood pressure*
- Although the patient has **hypertension** (142/86 mmHg), the primary driver for a beta-blocker from a START perspective here is his **systolic heart failure**, not specifically uncontrolled blood pressure.
- Beta-blockers are not typically the first-line addition for **hypertension** when an ACE inhibitor is already in use, unless there's a compelling comorbidity like heart failure.
*Beta-blockers are recommended in diabetes to reduce cardiovascular risk*
- While beta-blockers can be used in **diabetes**, the START criteria do not broadly recommend them solely for **cardiovascular risk reduction** in all diabetic patients.
- The patient is already receiving **ramipril** and **simvastatin**, which are key for cardiovascular and renal protection in **Type 2 Diabetes**.
*Beta-blockers should replace digoxin in elderly patients with heart failure*
- Beta-blockers and **digoxin** often serve complementary roles in managing patients with both **heart failure and atrial fibrillation** and are not mutually exclusive.
- The **START criteria** aim to identify important medications that are *missing* rather than promoting the *replacement* of an existing, potentially beneficial drug like digoxin.
Question 158: A 69-year-old man with COPD, ischaemic heart disease, type 2 diabetes, and depression presents with recurrent falls. He is taking tiotropium 18mcg OD, salmeterol/fluticasone 25/250mcg BD, bisoprolol 5mg OD, aspirin 75mg OD, atorvastatin 40mg OD, metformin 1g BD, lisinopril 10mg OD, mirtazapine 30mg nocte, and diazepam 5mg BD for anxiety. Examination shows postural hypotension (lying BP 138/82 mmHg, standing BP 110/68 mmHg). Which medication change would most effectively reduce his fall risk while maintaining optimal chronic disease management?
A. Stop bisoprolol as beta-blockers cause postural hypotension
B. Stop tiotropium as anticholinergics increase fall risk in elderly
C. Reduce lisinopril dose to 5mg OD to address postural hypotension
D. Switch mirtazapine to sertraline to reduce sedation
E. Stop diazepam and address anxiety with psychological interventions (Correct Answer)
Explanation: ***Stop diazepam and address anxiety with psychological interventions***
- **Benzodiazepines** like **diazepam** are strongly associated with increased fall risk in the elderly due to **central nervous system (CNS) depression**, leading to **sedation**, impaired coordination, and prolonged reaction times.
- The **STOPP/START criteria** explicitly recommend avoiding benzodiazepines in patients with a history of falls, especially considering diazepam's **long half-life** and its lack of mortality benefit for chronic physiological conditions.
*Stop bisoprolol as beta-blockers cause postural hypotension*
- **Bisoprolol** is a crucial medication for the management of **ischaemic heart disease**, reducing morbidity and mortality. Abrupt discontinuation can lead to **rebound tachycardia** or worsening angina.
- While beta-blockers can influence blood pressure, the primary driver of **postural hypotension** in this patient is likely multifactorial. Stopping a **cardioprotective agent** without a strong indication would compromise essential chronic disease management.
*Stop tiotropium as anticholinergics increase fall risk in elderly*
- **Tiotropium** is a long-acting muscarinic antagonist (LAMA) vital for **COPD symptom control** and reducing exacerbation frequency.
- Inhaled anticholinergics like tiotropium have **minimal systemic absorption** compared to oral anticholinergics, making them far less likely to contribute significantly to falls or cognitive impairment.
*Reduce lisinopril dose to 5mg OD to address postural hypotension*
- **Lisinopril** is an angiotensin-converting enzyme (ACE) inhibitor crucial for managing **hypertension**, **ischaemic heart disease**, and **renal protection** in type 2 diabetes, benefits which could be compromised by dose reduction.
- While lisinopril contributes to blood pressure regulation, addressing the more significant and modifiable sedative medication (diazepam) is a higher priority for **fall prevention**.
*Switch mirtazapine to sertraline to reduce sedation*
- Although **mirtazapine** can cause sedation, it is treating a primary condition (depression); switching antidepressants can be complex and may destabilize his mood.
- **Sertraline** (an SSRI) also carries its own set of risks in the elderly, including potential for **hyponatremia** and gastrointestinal side effects, and some SSRIs have also been associated with an increased fall risk. **Diazepam** presents a more direct and readily reversible fall risk.
Question 159: You are conducting a medication review for a 75-year-old woman with type 2 diabetes, ischaemic heart disease, heart failure (NYHA class II), and chronic kidney disease stage 3a. Her medications include metformin 1g BD, gliclazide 160mg BD, ramipril 10mg OD, bisoprolol 10mg OD, furosemide 40mg OD, spironolactone 25mg OD, aspirin 75mg OD, and atorvastatin 80mg OD. Her HbA1c is 52 mmol/mol, eGFR is 48 mL/min/1.73m², and potassium is 5.2 mmol/L. Which medication requires the most urgent review?
A. Metformin should be stopped due to renal impairment
B. Ramipril should be stopped temporarily to manage potassium
C. Spironolactone should be stopped due to hyperkalaemia risk (Correct Answer)
D. Gliclazide dose is excessive and should be reduced
E. Bisoprolol should be reduced as it may be causing fatigue
Explanation: ***Spironolactone should be stopped due to hyperkalaemia risk***- The patient has **hyperkalaemia** (potassium 5.2 mmol/L, with a normal range typically up to 5.0) which is significantly exacerbated by the combination of an **ACE inhibitor** (ramipril) and a **mineralocorticoid receptor antagonist (MRA)** in the presence of **CKD stage 3a**.- While beneficial for **heart failure**, MRAs carry a high risk of life-threatening hyperkalaemia, especially when the **eGFR** is reduced, making it the most urgent medication to review and likely discontinue.*Metformin should be stopped due to renal impairment*- Metformin only requires a dose reduction when the **eGFR** falls below 45 mL/min/1.73m² and should be stopped completely if it falls below **30 mL/min/1.73m²**.- With an **eGFR of 48 mL/min/1.73m²**, the current dose is acceptable, though it warrants close monitoring as the patient approaches the threshold for reduction.*Ramipril should be stopped temporarily to manage potassium*- **ACE inhibitors** (like ramipril) provide critical cardio-renal protection in patients with **heart failure** and **diabetes**.- Potassium should be managed by first stopping non-essential potassium-elevating agents (like MRAs) or addressing diet before considering stopping the **ACE inhibitor**.*Gliclazide dose is excessive and should be reduced*- A dose of **160mg BD** is within the standard therapeutic range for gliclazide, and an **HbA1c of 52 mmol/mol** suggests the patient has good glycemic control and is not experiencing significant hypoglycaemia.- While dose adjustments might be considered to simplify the regimen, this does not present an acute safety risk comparable to **electrolyte imbalances**.*Bisoprolol should be reduced as it may be causing fatigue*- **Bisoprolol 10mg** is a standard target dose for the management of **heart failure (NYHA class II)** to improve long-term survival and reduce mortality.- Fatigue is a common side effect of **beta-blockers**, but dose reduction is not urgently required unless there is severe **bradycardia**, **hypotension**, or other significant adverse effects compromising the patient's stability.
Question 160: An 82-year-old man with heart failure, chronic kidney disease stage 3b, benign prostatic hyperplasia, and insomnia has been taking temazepam 10mg nocte for the past 8 years. He attends asking for a repeat prescription. His other medications include furosemide 40mg OD, ramipril 5mg OD, bisoprolol 2.5mg OD, and tamsulosin 400mcg OD. He reports that the temazepam 'works well' and he is reluctant to stop it. What is the most appropriate management approach regarding his benzodiazepine use?
A. Stop temazepam immediately and commence zopiclone as an alternative
B. Explain the risks and offer a gradual withdrawal plan with reduction of 2mg every 2 weeks (Correct Answer)
C. Continue temazepam but reduce the dose to 5mg to minimize harm
D. Prescribe 2 weeks only and advise he must see a psychiatrist for ongoing management
E. Continue temazepam as it is clearly effective and he has been stable on it for years
Explanation: ***Explain the risks and offer a gradual withdrawal plan with reduction of 2mg every 2 weeks***
- Long-term use of **benzodiazepines** in the elderly increases the risk of **falls**, **cognitive impairment**, and fractures; a **gradual taper** is essential to prevent severe withdrawal symptoms after 8 years of use.
- **NICE guidelines** and **STOPP criteria** recommend a slow reduction (often 1/8 to 1/4 of the dose every 1-2 weeks) while providing patient education on the long-term benefits of cessation.
*Stop temazepam immediately and commence zopiclone as an alternative*
- **Abrupt cessation** of long-term benzodiazepines is dangerous and can precipitate **seizures**, **delirium**, or severe rebound insomnia.
- **Zopiclone** is a 'Z-drug' with a similar safety profile and risk of **dependence** and **falls** as benzodiazepines, making it an inappropriate substitute in the elderly.
*Continue temazepam but reduce the dose to 5mg to minimize harm*
- While lower doses reduce some risks, a simple dose reduction without a structured **withdrawal protocol** does not address the underlying **physiological dependence**.
- This approach lacks the necessary patient collaboration and **monitoring** required to successfully transition the patient off the medication permanently.
*Prescribe 2 weeks only and advise he must see a psychiatrist for ongoing management*
- Managing benzodiazepine withdrawal is a routine part of **primary care**; a referral to a **psychiatrist** is generally unnecessary unless there are complex co-morbid mental health issues.
- Setting a rigid 2-week limit without an agreed **tapering plan** may damage the doctor-patient relationship and lead to patient distress or unsafe sourcing of medication.
*Continue temazepam as it is clearly effective and he has been stable on it for years*
- Stability does not equate to safety; the patient has multiple risk factors including **advanced age** and **polypharmacy** that heighten the risk of **adverse drug events**.
- Physicians have a duty to periodically review and discuss the **deprescribing** of potentially inappropriate medications, even if the patient believes they are beneficial.
